7 Investor presentation First six months of 2020 Sales growth of 7% at CER, driven International Operations Reported sales split for the first half of 2020 DKK billion 40 35 Insulin GLP-1 Growth at CER 12% Other diabetes Obesity 30 International Operations 25 20 11% 15 14% 10 12% 5 0 IO EMEA China RoW Biopharm 1% NAO IO: International Operations; EMEA: Europe, Middle East, and Africa; China: Mainland China, Hong Kong, Taiwan; RoW: Rest of Worl
Download PDF file